TAFI inhibitors (Berlex)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameTAFI inhibitors (Berlex)
Drug Alias NameBX-528
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPlasminogen modulatorsCarboxypeptidase B2 isoform A inhibitors
TargetsCarboxypeptidase B2 isoform APlasminogen
Therapy Area/IndicationsThrombosisMyocardial InfarctionCoronary Thrombosis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBerlex Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBerlex Biosciences Inc
Active IndicationsN/A
Inactive IndicationsThrombosisMyocardial InfarctionCoronary Thrombosis +[4] 

Other Information

ATC CodeN/A
Related LinksN/A